Empowering Primary Care Through Evidence

PEER is a primary care led evidence based medicine team focused on providing relevant evidence to family physicians and primary care providers.

The PEER Simplified Lipid Guideline

Updated for 2023! A simplified approach to lipid management for busy family doctors! Practical summary for clinicians. Evidence-based recommendations for lipid management. Useful online decision aid. Easy-to-read patient handout.

CFPCLearn’s primary care focused library includes a variety of content including evidence summaries, videos, podcasts and interactive learning courses to support clinicians in their practice.

PEIP Conference 2023

Another great PEIP conference occurred October 20-21, 2023. 

 We had over 600 attendees, both in-person and online, who enjoyed the mixture of concise, to-the-point presentations which blended humour with serious learning.  We were thrilled to have outstanding speakers who focused on practical, applicable knowledge.  From “Bodies Behaving Badly” to practical sessions on Orthopedics, the diversity and richness of content offered something valuable for all primary care professionals. 

We’re excited to announce that PEIP 2024 is scheduled for October 18-19, 2024. Whether you prefer to join us in person or online, we promise another round of engaging, insightful, and fun sessions.

Most Recent Tools for Practice

Tools for Practice #362 – Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?

At ~24 weeks, ~80-90% of females report improvement in their acne with COCs, compared to 50-80% placebo, and 30-50% will have clear-almost clear skin versus 10-40% on placebo. Efficacy appears similar between individual COCs. Spironolactone, typically added to topical agents, has similar outcomes. Discontinuations due to adverse events appear comparable to placebo. Read More

Tools for Practice #361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?

In high-risk infants (premature and/or congenital heart or lung conditions), palivizumab (4-5 doses monthly during RSV season) reduces RSV hospitalization (4.5% versus 10% placebo). Nirsevimab (one dose) reduces RSV hospitalizations in healthy premature infants (0.8% versus 4%) and term infants (0.3-0.4% versus 1.5-2.0%). Side effects are similar to placebo. Read More

Tools for Practice #360 Ketamine for Depression

What are the benefits and harms of ketamine/esketamine for depression?

Ketamine/esketamine appears effective for moderate-severe depression (helping 10-20% more people respond over placebo at 1-4 weeks). However, biases are very common and large effects are likely exaggerated. Adverse events are common (example: 20% more nausea/vomiting). Considerable uncertainty remains (treating mid/long-term, misuse risk, and long-term harms) and treatment is costly. Read More

Tools for Practice #359 Topical corticosteroids for atopic dermatitis – More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?

Evidence is somewhat limited but topical corticosteroids are effective for atopic dermatitis and efficacy likely increases with potency. Once daily seems similarly effective to twice daily. If frequent flares, ‘weekend therapy’ (treatment 2-days/week to areas with recurrent flares) will help ~60% avoid a flare versus ~30% using placebo-cream over 16-weeks. Topical corticosteroids are well-tolerated for ≤6 weeks. Long-term harms are not available. Read More

Tools for Practice #358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?

Potential benefits of cranberry products for UTI prevention are at high risk-of-bias from potential publication bias, small studies, and unblinding. If biases disregarded, cranberry products might reduce the proportion of women with recurrent UTIs from 24% to 18% over ≤1 year. Results are inconsistent between patient populations; example children with recurrent UTIs may benefit but not institutionalized elderly or pregnant woman. Read More

Congratulations to PEER's Tina Korownyk: Alberta Family Physician of the Year

PEER Director, Dr. Tina Korownyk was awarded the 2023 Alberta Family Physician of the year at the annual Family Medicine Forum gala in Montreal, Quebec on November 10. The PEER team joined Tina to celebrate her achievement as a wonderful physician and leader in primary care. Congratulations Tina!

PEER Values

When creating primary care education and programs, the PEER team focuses on minimizing bias, patient orientated outcomes, shared decision making, collaboration and most importantly simplicity.

Who is PEER?

Patients, Experience, Evidence and Research (PEER) was formed between a group of primary care providers who shared a common belief that evidence should be made accessible to all primary care providers. 

Follow @peerevidence on Instagram

Our Partners

Sign Up for the PEER Newsletter

Don’t miss out on the latest from PEER. Get first access the latest PEER research and notified when PEER releases new guidelines and tools.